HANGZHOU, China, July 24, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:RDGT) (&#34;Ridgetech&#34; or the &#34;Company&#34;), a wholesale distributor of pharmaceutical and other healthcare products in China, today

HANGZHOU, China, July 24, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RDGT">RDGT</a>) (&#34;Ridgetech&#34; or the &#34;Company&#34;), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that its wholly owned offline pharmaceutical wholesale distribution platform, Zhejiang Jiuxin Medicine Co., Ltd. (&#34;Jiuxin Medicine&#34;), has been elected as a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association (the &#34;Association&#34;), which is scheduled to be officially inaugurated on July 28, 2026. The appointment reflects industry recognition of Jiuxin Medicine&#39;s efforts to advance pharmaceutical supply chain transparency and its pioneering implementation of full-variety drug traceability code scanning across Zhejiang Province.
Association Mandate and Industry RecognitionThe Association was established to promote the high-quality development of the regional biomedical sector, encompassing pharmaceuticals, medical devices, and cosmetics. In March 2026, a delegation of officials and regulators from the Zhejiang Medical Products Administration (the &#34;MPA&#34;) conducted an on-site inspection of Jiuxin Medicine to assess the operational effectiveness of its full-variety drug traceability code scanning initiative, gather feedback from pharmaceutical manufacturers, and facilitate cross-sector collaboration on the development of province-wide traceability infrastructure. During the visit, the MPA recognized Jiuxin Medicine&#39;s progress in implementing the initiative and encouraged continued collaboration to further enhance the intelligence and efficiency of traceability management while balancing regulatory compliance with operational efficiency.Technology-Enabled Distribution ExcellenceUnder Ridgetech&#39;s dual-engine strategic framework, Jiuxin Medicine and Allright (Hangzhou) Internet Technology Co., Ltd. (&#34;Allright&#34;), the Company&#39;s online pharmaceutical and healthcare products distribution platform, serve as two core growth pillars. Jiuxin Medicine primarily focuses on B2B pharmaceutical distribution and supply chain solutions, while strategically collaborating with Allright to advance the integration of Ridgetech&#39;s pharmaceutical and healthcare ecosystem.In its operations, Jiuxin Medicine leverages AI-enabled technologies and big-data analytics in conjunction with the drug traceability code system to enhance real-time visibility across the distribution process, enabling timely and accurate identification, interception, and traceability of pharmaceutical products when necessary. The Company is also actively exploring opportunities to leverage traceability data to identify transportation and distribution bottlenecks in real time, with the goal of optimizing efficiency across the broader supply chain network.Policy Context: The National Drug Traceability ReformZhejiang Province is among China&#39;s pioneering regions in advancing comprehensive drug traceability reform. Through the implementation of full-variety drug traceability code scanning, Zhejiang has taken a leading role in establishing a traceability framework designed to cover the full lifecycle of pharmaceutical products.The drug traceability code is a unique electronic identifier assigned to individual pharmaceutical packages, enabling relevant parties to record and track the movement of products throughout the supply chain. The traceability framework requires key stages of the pharmaceutical lifecycle—including manufacturer shipment, wholesale receipt and outbound distribution, retail pharmacy and hospital receipt, and dispensing—to be recorded through traceability code scanning. In applicable scenarios, successful traceability code scanning is linked to medical insurance settlement under the &#34;payment based on code&#34; mechanism.Under the national drug traceability reform roadmap, full traceability data uploads became mandatory for designated healthcare providers effective January 1, 2026.Management CommentaryMr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented: &#34;We are truly honored that Jiuxin Medicine has been elected as a vice-president unit of the Association. This recognition is a testament to our achievements to date and a meaningful call to action for our future endeavors. As Zhejiang continues to advance national drug traceability reform, we are committed to remaining at the forefront of compliance, innovation, and operational excellence.&#34;Our dual-engine strategy, anchored by Jiuxin Medicine&#39;s offline B2B distribution capabilities and Allright&#39;s online distribution platform, positions us to capture synergies across the pharmaceutical value chain. We believe that through disciplined execution and the deeper integration of emerging technologies, including AI and big data, we can continue to strengthen our competitive advantages, enhance supply chain resilience, and pursue sustainable, high-quality growth across our pharmaceutical ecosystem.&#34;About Ridgetech, Inc.Ridgetech, Inc. (&#34;Ridgetech&#34; or the &#34;Company&#34;), is a growing online and offline wholesale distributor of pharmaceutical and other healthcare products in China. Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. For more information about the Company, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.ridgetch.com/" target="_blank" rel="nofollow">www.ridgetch.com</a>. The Company routinely posts important information on its website.Forward-Looking StatementsCertain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the Company&#39;s business strategies, growth initiatives, operational capabilities, and anticipated benefits from its pharmaceutical distribution, supply chain, and ecosystem development activities. Investors can identify these forward-looking statements by words or phrases such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;aim,&#34; &#34;estimate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;is/are likely to,&#34; or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Factors that could cause actual results or events to differ materially from those reflected in the Company&#39;s forward-looking statements including risks related to the Company&#39;s ability to satisfy applicable procurement conditions, changes in market demand, the Company&#39;s ability to successfully implement and promote its digital platform, and those other risks described in the Company&#39;s most recent registration statement, most recent annual report on Form 20-F and in its other filings with the U.S. Securities and Exchange Commission.For more information, please contact:Company Contact: Frank Zhao Interim Chief Executive Officer and Chief Financial Officer +86-571-88077108 <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:frank.zhao@ridgetch.com" target="_blank" rel="nofollow">frank.zhao@ridgetch.com</a>Investor Relations Contact:Tina Xiao Ascent Investor Relations LLC +1-646-932-7242 <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investors@ascent-ir.com" target="_blank" rel="nofollow">investors@ascent-ir.com</a>



<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=CN11569&amp;sd=2026-07-24"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/ridgetech-strengthens-pharmaceutical-ecosystem-leadership-with-vice-president-role-in-zhejiang-biomedical-association-302833883.html" target="_blank">https://www.prnewswire.com/news-releases/ridgetech-strengthens-pharmaceutical-ecosystem-leadership-with-vice-president-role-in-zhejiang-biomedical-association-302833883.html</a>SOURCE Ridgetech, Inc.

RDGT

Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association

Ridgetech gains regulatory recognition as Jiuxin Medicine joins local association leadership

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 HANGZHOU, China, July 24, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:RDGT) (&amp;#34;Ridgetech&amp;#34; or the &amp;#34;Company&amp;#34;), a wholesale distributor of pharmaceutical and other healthcare products in China, today
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Ridgetech announced Jiuxin Medicine was elected as a vice-president unit of the Hangzhou Qiantang District Association, underscoring regulatory alignment and leadership in drug traceability. The move comes amid Zhejiang&#039;s push for full-variety traceability and a March 2026 MPA inspection praising Jiuxin&#039;s progress, while Ridgetech emphasizes AI-enabled, two-pronged distribution that could lift efficiency and growth.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Jiuxin Medicine named vice-president unit of Hangzhou association; signals industry recognition. Could boost credibility and distribution partnerships.</li><li>Association inauguration on July 28 highlights regulatory alignment with traceability goals. Supports Jiuxin&#039;s expansion opportunities.</li><li>Zhejiang&#039;s traceability reforms mandate full data uploads for providers from Jan 1, 2026. Benefits platforms with AI-driven traceability.</li><li>Ridgetech&#039;s dual-engine model and AI/big data aim to boost efficiency. Potential revenue growth in China.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Ridgetech, Inc. (RDGT): Subject of the release; potential uplift from regulatory and ecosystem developments.</li><li>Jiuxin Medicine (N/A): Offline B2B distribution platform; elected vice-president unit; regulatory alignment.</li><li>Allright (Hangzhou) Internet Technology Co., Ltd. (N/A): Online platform; core growth pillar alongside Jiuxin Medicine.</li><li>Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association (N/A): Association extending industry recognition and potential collaboration.</li><li>Zhejiang Medical Products Administration (MPA) (N/A): Regulator; conducted March 2026 inspection of Jiuxin Medicine; progress acknowledged.</li></ul>
 </section>

 <section data-block="category">
 <h3>Industry News</h3>
 Category: Industry News. The piece highlights regulatory-driven corporate development and ecosystem collaboration in China, relevant to RDGT&#039;s growth profile and potential multiple expansion from traceability spend.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Jiuxin Medicine named vice-president unit; potential uplift to RDGT&#039;s Zhejiang distribution.</li><li>Inauguration on July 28 may trigger positive sentiment and near-term trading activity.</li><li>January 1, 2026 data-upload mandate reinforces sector-wide tailwinds for traceability players.</li><li>AI/big data-enabled efficiency gains could improve margins and network resilience.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Jiuxin Medicine elected vice-president unit of Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association; inauguration date July 28, 2026.</li><li>Full-variety drug traceability scanning and data uploads mandated for designated healthcare providers from January 1, 2026.</li><li>Zhejiang Medical Products Administration conducted on-site inspection of Jiuxin Medicine in March 2026; progress recognized.</li><li>Ridgetech&#039;s dual-engine framework centers on Jiuxin Medicine offline B2B and Allright online distribution.</li><li>Frank Zhao, RDGT Interim CEO/CFO, commented on compliance, innovation, and growth opportunities.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 RDGT could rally in the near term on traceability reforms and Jiuxin&#039;s leadership, barring regulatory delays.
 </section>
</section>


HANGZHOU, China, July 24, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RDGT">RDGT</a>) (&#34;Ridgetech&#34; or the &#34;Company&#34;), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that its wholly owned offline pharmaceutical wholesale distribution platform, Zhejiang Jiuxin Medicine Co., Ltd. (&#34;Jiuxin Medicine&#34;), has been elected as a vice-president unit of the Hangzhou Qiantang District Biomedical and Cosmetic High-Quality Development Association (the &#34;Association&#34;), which is scheduled to be officially inaugurated on July 28, 2026. The appointment reflects industry recognition of Jiuxin Medicine&#39;s efforts to advance pharmaceutical supply chain transparency and its pioneering implementation of full-variety drug traceability code scanning across Zhejiang Province.
Association Mandate and Industry RecognitionThe Association was established to promote the high-quality development of the regional biomedical sector, encompassing pharmaceuticals, medical devices, and cosmetics. In March 2026, a delegation of officials and regulators from the Zhejiang Medical Products Administration (the &#34;MPA&#34;) conducted an on-site inspection of Jiuxin Medicine to assess the operational effectiveness of its full-variety drug traceability code scanning initiative, gather feedback from pharmaceutical manufacturers, and facilitate cross-sector collaboration on the development of province-wide traceability infrastructure. During the visit, the MPA recognized Jiuxin Medicine&#39;s progress in implementing the initiative and encouraged continued collaboration to further enhance the intelligence and efficiency of traceability management while balancing regulatory compliance with operational efficiency.Technology-Enabled Distribution ExcellenceUnder Ridgetech&#39;s dual-engine strategic framework, Jiuxin Medicine and Allright (Hangzhou) Internet Technology Co., Ltd. (&#34;Allright&#34;), the Company&#39;s online pharmaceutical and healthcare products distribution platform, serve as two core growth pillars. Jiuxin Medicine primarily focuses on B2B pharmaceutical distribution and supply chain solutions, while strategically collaborating with Allright to advance the integration of Ridgetech&#39;s pharmaceutical and healthcare ecosystem.In its operations, Jiuxin Medicine leverages AI-enabled technologies and big-data analytics in conjunction with the drug traceability code system to enhance real-time visibility across the distribution process, enabling timely and accurate identification, interception, and traceability of pharmaceutical products when necessary. The Company is also actively exploring opportunities to leverage traceability data to identify transportation and distribution bottlenecks in real time, with the goal of optimizing efficiency across the broader supply chain network.Policy Context: The National Drug Traceability ReformZhejiang Province is among China&#39;s pioneering regions in advancing comprehensive drug traceability reform. Through the implementation of full-variety drug traceability code scanning, Zhejiang has taken a leading role in establishing a traceability framework designed to cover the full lifecycle of pharmaceutical products.The drug traceability code is a unique electronic identifier assigned to individual pharmaceutical packages, enabling relevant parties to record and track the movement of products throughout the supply chain. The traceability framework requires key stages of the pharmaceutical lifecycle—including manufacturer shipment, wholesale receipt and outbound distribution, retail pharmacy and hospital receipt, and dispensing—to be recorded through traceability code scanning. In applicable scenarios, successful traceability code scanning is linked to medical insurance settlement under the &#34;payment based on code&#34; mechanism.Under the national drug traceability reform roadmap, full traceability data uploads became mandatory for designated healthcare providers effective January 1, 2026.Management CommentaryMr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented: &#34;We are truly honored that Jiuxin Medicine has been elected as a vice-president unit of the Association. This recognition is a testament to our achievements to date and a meaningful call to action for our future endeavors. As Zhejiang continues to advance national drug traceability reform, we are committed to remaining at the forefront of compliance, innovation, and operational excellence.&#34;Our dual-engine strategy, anchored by Jiuxin Medicine&#39;s offline B2B distribution capabilities and Allright&#39;s online distribution platform, positions us to capture synergies across the pharmaceutical value chain. We believe that through disciplined execution and the deeper integration of emerging technologies, including AI and big data, we can continue to strengthen our competitive advantages, enhance supply chain resilience, and pursue sustainable, high-quality growth across our pharmaceutical ecosystem.&#34;About Ridgetech, Inc.Ridgetech, Inc. (&#34;Ridgetech&#34; or the &#34;Company&#34;), is a growing online and offline wholesale distributor of pharmaceutical and other healthcare products in China. Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. For more information about the Company, please visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.ridgetch.com/" target="_blank" rel="nofollow">www.ridgetch.com</a>. The Company routinely posts important information on its website.Forward-Looking StatementsCertain statements in this press release are forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the Company&#39;s business strategies, growth initiatives, operational capabilities, and anticipated benefits from its pharmaceutical distribution, supply chain, and ecosystem development activities. Investors can identify these forward-looking statements by words or phrases such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;aim,&#34; &#34;estimate,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;believe,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;is/are likely to,&#34; or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Factors that could cause actual results or events to differ materially from those reflected in the Company&#39;s forward-looking statements including risks related to the Company&#39;s ability to satisfy applicable procurement conditions, changes in market demand, the Company&#39;s ability to successfully implement and promote its digital platform, and those other risks described in the Company&#39;s most recent registration statement, most recent annual report on Form 20-F and in its other filings with the U.S. Securities and Exchange Commission.For more information, please contact:Company Contact: Frank Zhao Interim Chief Executive Officer and Chief Financial Officer +86-571-88077108 <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:frank.zhao@ridgetch.com" target="_blank" rel="nofollow">frank.zhao@ridgetch.com</a>Investor Relations Contact:Tina Xiao Ascent Investor Relations LLC +1-646-932-7242 <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:investors@ascent-ir.com" target="_blank" rel="nofollow">investors@ascent-ir.com</a>



<img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=CN11569&amp;sd=2026-07-24"></img> View original content:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/ridgetech-strengthens-pharmaceutical-ecosystem-leadership-with-vice-president-role-in-zhejiang-biomedical-association-302833883.html" target="_blank">https://www.prnewswire.com/news-releases/ridgetech-strengthens-pharmaceutical-ecosystem-leadership-with-vice-president-role-in-zhejiang-biomedical-association-302833883.html</a>SOURCE Ridgetech, Inc.

Ridgetech announced Jiuxin Medicine was elected as a vice-president unit of the Hangzhou Qiantang District Association, underscoring regulatory alignment and leadership in drug traceability. The move comes amid Zhejiang's push for full-variety traceability and a March 2026 MPA inspection praising Jiuxin's progress, while Ridgetech emphasizes AI-enabled, two-pronged distribution that could lift efficiency and growth.

News insight

Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association

AI summary

Sentiment rationale

Key facts

Industry News